Telitacicept for early diffuse scleroderma
Treatments studied
Part of Skin clinical trials.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with diffuse systemic sclerosis (scleroderma) by a doctor using official criteria.
- Your first non-Raynaud's symptom (like skin thickening or joint pain) started no more than 18 months ago.
- Your skin tightness score (mRSS) is at least 10 at the screening visit.
- You have not taken rituximab, belimumab, or other B-cell therapies before.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
This trial tests a new medicine called telitacicept for people with connective tissue disease (like lupus or Sjögren's) whose platelet counts stay dangerously low despite standard treatments. It aims to raise platelet levels and reduce bleeding risk.
This trial tests if a new medication, telitacicept, is safe and effective for people with difficult-to-treat rheumatoid arthritis. It may be an option for patients who have not found relief from other treatments.
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.